Date Filed | Type | Description |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/14/2023 |
8-K
| Quarterly results |
08/08/2023 |
8-K
| Investor presentation |
07/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/25/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
05/30/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 12.5% stake in Icosavax, Inc. |
05/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
05/23/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/10/2023 |
8-K
| Quarterly results |
04/19/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/19/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/19/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
02/14/2023 |
5
| Russo Thomas Joseph (CFO) has filed a Form 5 on Icosavax, Inc. |
02/14/2023 |
5
| Kanesa-thasan Niranjan (Chief Medical Officer) has filed a Form 5 on Icosavax, Inc. |
02/14/2023 |
5
| Holtzman Douglas (Chief Scientific Officer) has filed a Form 5 on Icosavax, Inc. |
02/14/2023 |
5
| Cearley Cassia (Chief Business Officer) has filed a Form 5 on Icosavax, Inc. |
02/14/2023 |
SC 13G/A
| NanoDimension III, L.P. reports a 3.2% stake in Icosavax, Inc. |
02/09/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
01/10/2023 |
SC 13G
| T. Rowe Price Investment Management, Inc. reports a 11.2% stake in ICOSAVAX INC |
01/10/2023 |
SC 13G
| FMR LLC reports a 12.2% stake in ICOSAVAX INC |
12/21/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
12/13/2022 |
8-K
| Quarterly results |
11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/14/2022 |
8-K
| Quarterly results |
08/30/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
08/15/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/15/2022 |
8-K
| Quarterly results |
06/28/2022 |
8-K
| Quarterly results |
|